I bet management would appreciate interest in POTP expressed in the form of questions at the CC this afternoon. Details about the call below.
Press Release Source: Point Therapeutics, Inc.
Point Therapeutics to Host Second Quarter 2006 Results Conference Call/Audio Webcast
Wednesday August 2, 8:23 am ET
BOSTON--(BUSINESS WIRE)--Aug. 2, 2006--Point Therapeutics, Inc. (NASDAQ: POTP - News), announced today that it will release second quarter 2006 results on Tuesday, August 8, 2006, after the close of the U.S. financial markets. A conference call will follow at 4:30 PM Eastern Time, to review the results and provide an update on the Company's progress.
ADVERTISEMENT
Participants are invited to attend the call by visiting www.pther.com or by dialing:
866-202-3048 (International: 617-213-8843)
Passcode: 12632977
A re-broadcast of the conference call will be available until August 15, 2006 and accessible by dialing:
888-286-8010 (International: 617-801-6888)
Passcode: 51903272
About Point Therapeutics, Inc.:
Point is a Boston-based biopharmaceutical company developing a portfolio of dipeptidyl peptidase (DPP) inhibitors for use in cancer, type 2 diabetes and as vaccine adjuvants. Point is currently studying its lead product candidate, talabostat, in two Phase 3 trials in non-small cell lung cancer. Point is also studying talabostat in several Phase 2 trials, including as a single-agent in metastatic melanoma, in combination with cisplatin in metastatic melanoma, in combination with rituximab in advanced chronic lymphocytic leukemia, and in combination with gemcitabine in metastatic pancreatic cancer. In addition, Point's portfolio includes two other DPP inhibitors in preclinical development--PT-630 for type 2 diabetes, and PT-510 as a vaccine adjuvant.
Contact:
Point Therapeutics, Inc.
Sarah Cavanaugh, 617-933-7508
Director, Corporate Communications |
